Logo image of IMRN

IMMURON LTD-SPON ADR (IMRN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMRN - US45254U1016 - ADR

1.71 USD
-0.04 (-2.29%)
Last: 11/28/2025, 7:39:16 PM
Fundamental Rating

3

Taking everything into account, IMRN scores 3 out of 10 in our fundamental rating. IMRN was compared to 533 industry peers in the Biotechnology industry. The financial health of IMRN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, IMRN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMRN has reported negative net income.
IMRN had a negative operating cash flow in the past year.
In the past 5 years IMRN always reported negative net income.
In the past 5 years IMRN always reported negative operating cash flow.
IMRN Yearly Net Income VS EBIT VS OCF VS FCFIMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

Looking at the Return On Assets, with a value of -51.49%, IMRN is in line with its industry, outperforming 47.75% of the companies in the same industry.
IMRN's Return On Equity of -64.64% is in line compared to the rest of the industry. IMRN outperforms 59.18% of its industry peers.
Industry RankSector Rank
ROA -51.49%
ROE -64.64%
ROIC N/A
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
IMRN Yearly ROA, ROE, ROICIMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

IMRN's Gross Margin of 65.39% is fine compared to the rest of the industry. IMRN outperforms 79.96% of its industry peers.
IMRN's Gross Margin has declined in the last couple of years.
IMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
IMRN Yearly Profit, Operating, Gross MarginsIMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMRN has been increased compared to 5 years ago.
There is no outstanding debt for IMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMRN Yearly Shares OutstandingIMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
IMRN Yearly Total Debt VS Total AssetsIMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

IMRN has an Altman-Z score of -5.94. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.
IMRN has a worse Altman-Z score (-5.94) than 64.61% of its industry peers.
There is no outstanding debt for IMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.94
ROIC/WACCN/A
WACC8.87%
IMRN Yearly LT Debt VS Equity VS FCFIMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

A Current Ratio of 5.09 indicates that IMRN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.09, IMRN is in line with its industry, outperforming 57.12% of the companies in the same industry.
A Quick Ratio of 4.19 indicates that IMRN has no problem at all paying its short term obligations.
IMRN has a Quick ratio (4.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.09
Quick Ratio 4.19
IMRN Yearly Current Assets VS Current LiabilitesIMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

IMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.66%, which is quite impressive.
The Revenue has grown by 48.63% in the past year. This is a very strong growth!
The Revenue has been growing by 23.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
Revenue 1Y (TTM)48.63%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%29.26%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMRN Yearly Revenue VS EstimatesIMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
IMRN Yearly EPS VS EstimatesIMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2018 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMRN Price Earnings VS Forward Price EarningsIMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMRN Per share dataIMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMURON LTD-SPON ADR

NASDAQ:IMRN (11/28/2025, 7:39:16 PM)

1.71

-0.04 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28
Earnings (Next)02-26 2026-02-26
Inst OwnersN/A
Inst Owner Change181.68%
Ins Owners6.64%
Ins Owner ChangeN/A
Market Cap11.88M
Revenue(TTM)7.29M
Net Income(TTM)-5.22M
Analysts0
Price TargetN/A
Short Float %0.28%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.68
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.49%
ROE -64.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.39%
FCFM N/A
ROA(3y)-37.77%
ROA(5y)-31.16%
ROE(3y)-46.18%
ROE(5y)-36.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5Y-2.08%
F-Score2
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.09
Quick Ratio 4.19
Altman-Z -5.94
F-Score2
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.14%
Cap/Sales(5y)1.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.07%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)48.63%
Revenue growth 3Y111.96%
Revenue growth 5Y23.67%
Sales Q2Q%29.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.37%
OCF growth 3YN/A
OCF growth 5YN/A

IMMURON LTD-SPON ADR / IMRN FAQ

What is the fundamental rating for IMRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMRN.


Can you provide the valuation status for IMMURON LTD-SPON ADR?

ChartMill assigns a valuation rating of 0 / 10 to IMMURON LTD-SPON ADR (IMRN). This can be considered as Overvalued.


Can you provide the profitability details for IMMURON LTD-SPON ADR?

IMMURON LTD-SPON ADR (IMRN) has a profitability rating of 1 / 10.